Abstract 141P
Background
Immunotherapy based on Immune Checkpoint Inhibitors (ICI) has changed the management of advanced Non-Small Cell Lung Cancer (NSCLC), achieving long-time responders for the first time. However, response rates remain below 40%. A deeper understanding of ICI response mechanisms and the identification of predictive biomarkers is still an urgent need. A close relation between DNA methylation and the immunogenic status of the tumor microenvironment (TME) has been recently proposed for several solid tumors. In this work we evaluated the epigenetic and transcriptomic status of NSCLC tumors before immunotherapy to disclose the possible role of DNA methylation in ICI response, and to identify immune-related signatures that predict ICI outcome.
Methods
We included 24 advanced NSCLC patients treated with anti-PD1 at first line. DNA and RNA were extracted from FFPE tumor biopsies. Genome-wide DNA methylation was quantified with the MethylationEPIC array and RNA-seq was performed with a NovaSeq6000 system. Data was annotated to the GRCh38 genome and bioinformatics was performed with R/Bioconductor.
Results
Differential methylation and expression patterns were found between patients with radiological response (n=10) and non-responder patients (n=14). We identified a DNA methylation signature that predicts a 6-months response to anti-PD1 therapy. Also, we reported a methylation profile associated with longer progression-free survival (PFS). Functional consequences of differential DNA methylation were confirmed by RNA-seq, identifying dysregulated immune pathways significantly enriched for both methylation and transcriptomic signatures. Pathways associated to ICI response related to T-cell and toll-like receptors signaling pathways, MHC-II complex, and interleukins. We also found aberrant methylation of the PI3K-Akt signaling pathway, which plays an essential role in the TME, regulating immune checkpoints and the sensitivity to ICI.
Conclusions
Overall, our results confirm that DNA methylation plays a role in the response to ICI in advanced NSCLC. These immune-related methylation profiles can predict response to anti-PD1 therapy and correlate with longer PFS, representing a source of predictive biomarkers for ICI outcome.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This research project is funded by the national Institute of Health Carlos III (ISCIII, PI21/00348). M.M-F. is supported by the Miguel Servet program (CP20/00188) from the ISCIII and the European Social Fund (“Investing in your future”).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract